Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7034067 in Non-ambulant Type 2 and 3 Spinal Muscular Atrophy
CTR20171612Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of risdiplam in spinal muscular atrophy type 2 (SMA2), Spinal muscular atrophy type 3 (SMA3), sponsored by Roche. Started Mar 2018; status: completed.
02
Drugs
risdiplam
03
Conditions
spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on CTR20171612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171612.